Reuters logo
in a month
BRIEF-Celgene International Sàrl announces results from phase 2a SLE-001 trial evaluating CC-220
June 14, 2017 / 3:11 PM / in a month

BRIEF-Celgene International Sàrl announces results from phase 2a SLE-001 trial evaluating CC-220

1 Min Read

June 14 (Reuters) - Celgene International Sàrl:

* Announced results from phase 2a SLE-001 trial evaluating CC-220, co's investigational, oral immunomodulatory compound

* Most common adverse events in trial were nausea, diarrhea and maculopapular rash

* No opportunistic infections or other systemic infections were reported in any CC-220 dose groups in trial

* Serious adverse events were reported in two patients in two highest CC-220 doses combined and in two patients in placebo group Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below